APA (7th ed.) Citation

RO, M., MS, S., CS, R., R, L., M, E., N, Y., . . . ME, F. (2024). Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: A Post Hoc Analysis of the TAILOR-PCI Study. Cardiovascular drugs and therapy, 38(3), 447. https://doi.org/10.1007/s10557-022-07392-2

Chicago Style (17th ed.) Citation

RO, Mathew, et al. "Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: A Post Hoc Analysis of the TAILOR-PCI Study." Cardiovascular Drugs and Therapy 38, no. 3 (2024): 447. https://doi.org/10.1007/s10557-022-07392-2.

MLA (9th ed.) Citation

RO, Mathew, et al. "Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: A Post Hoc Analysis of the TAILOR-PCI Study." Cardiovascular Drugs and Therapy, vol. 38, no. 3, 2024, p. 447, https://doi.org/10.1007/s10557-022-07392-2.